Overview

A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.
Phase:
Phase 1
Details
Lead Sponsor:
ContraVir Pharmaceuticals, Inc.
Treatments:
Hexadecyloxypropyl 9-(2-(phosphonomethoxy)propyl)adenine